Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-1-4614-7654-2_2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• CD133 expression in osteosarcoma and derivation of CD133⁺ cells.

  2013influential reference
• Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

  2013cited by this paper
• ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

  2013cited by this paper
• GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum.

  2012cited by this paper
• Aldehyde dehydrogenases and cell proliferation.

  2012cited by this paper
• Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

  2012cited by this paper
• Dietary approach in the prevention and treatment of NAFLD.

  2012cited by this paper
• Nestin and other putative cancer stem cell markers in pancreatic cancer

  2012influential reference
• Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

  2011cited by this paper
• The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

  2011cited by this paper
• Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer

  2011cited by this paper
• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling

  2011cited by this paper
• Cells of origin in cancer

  2011cited by this paper
• Update on the aldehyde dehydrogenase gene (ALDH) superfamily

  2011cited by this paper
• Colon cancer stem cells: implications in carcinogenesis.

  2011cited by this paper
• Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform

  2011cited by this paper
• ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma

  2011cited by this paper
• RAS and Hedgehog--partners in crime.

  2011cited by this paper
• Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

  2010cited by this paper
• Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance.

  2010cited by this paper
• Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin’s lymphoma

  2010cited by this paper
• The upgraded role of HER3 and HER4 receptors in breast cancer.

  2010cited by this paper
• Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers

  2010cited by this paper
• Functional and clinical relevance of chondroitin sulfate proteoglycan 4.

  2010cited by this paper
• Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

  2010cited by this paper
• Targeting Hedgehog — a Cancer Stem Cell Pathway

  2010cited by this paper
• CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

  2010cited by this paper
• ALDH1A1 Is a Marker for Malignant Prostate Stem Cells and Predictor of Prostate Cancer Patients’ Outcome

  2009cited by this paper
• Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells

  2009cited by this paper
• Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

  2009cited by this paper
• Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

  2009cited by this paper
• Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

  2008cited by this paper
• Cancer stem cell heterogeneity in hereditary breast cancer

  2008cited by this paper
• Antigens for cancer immunotherapy.

  2008cited by this paper
• Cancer vaccines: accomplishments and challenges.

  2008cited by this paper
• A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

  2008cited by this paper
• Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

  2007cited by this paper
• Effects of Low Confluency, Serum Starvation and Hypoxia on the Side Population of Cancer Cell Lines

  2007cited by this paper
• Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines

  2007cited by this paper
• HLA-G expression in human ovarian carcinoma counteracts NK cell function.

  2007cited by this paper
• Signaling Pathways in Cancer and Embryonic Stem Cells

  2007cited by this paper
• Enhancing immune responses for cancer therapy.

  2007cited by this paper
• Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

  2007cited by this paper
• Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.

  2007cited by this paper
• FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

  2007cited by this paper
• ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

  2007cited by this paper
• Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck.

  2007cited by this paper
• Cancer stem cells: an old idea--a paradigm shift.

  2006cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

  2006cited by this paper
• The epitope recognized by rituximab.

  2006cited by this paper
• The nucleation and maintenance of heterochromatin by a histone deacetylase in fission yeast.

  2005cited by this paper
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• Roles of heat shock protein gp96 in the ER quality control: redundant or unique function?

  2005cited by this paper
• Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.

  2005cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• Role of Human Aldehyde Dehydrogenases in Endobiotic and Xenobiotic Metabolism

  2004cited by this paper
• Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance.

  2004cited by this paper
• The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial

  2004cited by this paper
• The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape

  2004cited by this paper
• Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

  2003cited by this paper
• B7-H3: A costimulatory molecule for T cell activation and IFN-γ production

  2001cited by this paper
• B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

  2001cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2.

  1999cited by this paper
• Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity.

  1999cited by this paper
• GRP94, an ER chaperone with protein and peptide binding properties.

  1999cited by this paper
• Oral, Osmotic Minipump, and Intramuscular Administration to Sheep of the Veratrum Alkaloid Cyclopamine

  1989cited by this paper
• Effect of Isoniazid on Vitamin B6 Metabolism; Its Possible Significance in Producing Isoniazid Neuritis.∗

  1954cited by this paper

• B7-H3-targeted radioimmunotherapy of human cancer.

  2020cites this paper
• 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models

  2018cites this paper
• CSPG4 in osteosarcoma: functional roles and therapeutic potential

  2018cites this paper
• 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.

  2017influential citation
• Intracellular antigens as targets for antibody based immunotherapy of malignant diseases

  2015cites this paper